I-O Optimise:A novel multinational real-world research platform in thoracic malignancies by Ekman, Simon et al.
 
  
 
Aalborg Universitet
I-O Optimise
A novel multinational real-world research platform in thoracic malignancies
Ekman, Simon; Griesinger, Frank; Baas, Paul; Chao, David; Chouaid, Christos; O'donnell,
John C.; Penrod, John R.; Daumont, Melinda; Lacoin, Laure; Mckenney, Alexia;
Khovratovich, Masha; Munro, Robin E.J.; Durand-Zaleski, Isabelle; Johnsen, Søren Paaske
Published in:
Future Oncology
DOI (link to publication from Publisher):
10.2217/fon-2019-0025
Creative Commons License
CC BY-NC-ND 4.0
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Ekman, S., Griesinger, F., Baas, P., Chao, D., Chouaid, C., O'donnell, J. C., Penrod, J. R., Daumont, M., Lacoin,
L., Mckenney, A., Khovratovich, M., Munro, R. E. J., Durand-Zaleski, I., & Johnsen, S. P. (2019). I-O Optimise: A
novel multinational real-world research platform in thoracic malignancies. Future Oncology, 15(14), 1551-1563.
https://doi.org/10.2217/fon-2019-0025
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Methodology
For reprint orders, please contact: reprints@futuremedicine.com
I-O Optimise: a novel multinational
real-world research platform in thoracic
malignancies
Simon Ekman*,‡ ,1,2, Frank Griesinger‡ ,3, Paul Baas‡ ,4, David Chao‡ ,5, Christos Chouaid‡ ,6,
John C O’Donnell7, John R Penrod7, Melinda Daumont8, Laure Lacoin8, Alexia McKenney9,
Masha Khovratovich9, Robin EJ Munro9, Isabelle Durand-Zaleski‡ ,10 & Søren Paaske
Johnsen‡ ,11
1Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
2Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
3Department of Haematology & Oncology, University Department Internal Medicine-Oncology, Pius-Hospital, Medical Campus
University of Oldenburg, Oldenburg, Germany
4Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
5Department of Oncology, Royal Free Hospital, London, UK
6Pneumology Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France
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Aim: To describe I-O Optimise, a multinational program providing real-world insights into lung cancer
management. Materials & methods: Real-world data source selection for I-O Optimise followed a struc-
tured approach focused on population coverage, key variable capture, continuous/consistent data avail-
ability, record duration and data latency, and database expertise. Results: As of 31 October 2018, seven
real-world data sources were included in I-O Optimise, providing data on characteristics, treatment pat-
terns and clinical outcomes from more than 45,000 patients/year with non-small-cell lung cancer, small-cell
lung cancer and mesothelioma across Denmark, Norway, Portugal, Spain, Sweden and the UK. Conclusion:
The ongoing I-O Optimise initiative has the potential to provide a broad, robust and dynamic research
platform to continually address numerous research objectives in the lung cancer arena.
Lay abstract: This article describes the design and creation of I-O Optimise, a project that will collect
real-world evidence about patients with lung cancer across many different countries. A specific structured
approach was followed to select real-world data sources for inclusion in I-O Optimise and, as of 31 October
2018, seven real-world data sources were included, providing information on more than 45,000 patients
per year with lung cancer in Denmark, Norway, Portugal, Spain, Sweden and the UK. I-O Optimise is an
ongoing project that has the potential to provide information that will be important in improving the
care of patients with lung cancer.
First draft submitted: 15 January 2019; Accepted for publication: 19 February 2019; Published online:
11 March 2019
Keywords: clinical outcomes • database • mesothelioma • non-small-cell lung cancer • real-world evidence • small-
cell lung cancer • thoracic malignancies • treatment patterns
Lung cancer is the leading cause of cancer mortality worldwide [1]. Up to the late 1990s, pharmacological treat-
ments for advanced lung cancers were limited to platinum-based chemotherapy combinations, regardless of tumor
histology and without available options for subsequent treatment [2]. Significant advances in the understanding of
the complexity of lung tumor biology have resulted in the development of novel therapeutic agents for patients who
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meet appropriate criteria (e.g., targeted tyrosine kinase inhibitors) [3,4]. Recently, the advent of immunotherapies has
further transformed cancer management, including the treatment of lung cancer [5–7], with several immunotherapy
agents targeting the PD-1/PD-L1 axis now approved for the treatment of non-small-cell lung cancer (NSCLC)
and recommended in both European and US guidelines [8–10].
The increasing pace of change in the lung cancer treatment landscape and the range of therapeutic options
available necessitates complex clinical decision-making both for those responsible for delivering patient care
(e.g., oncologists and other healthcare professionals) and those responsible for deciding how limited resources
should be invested (e.g., payers and regulators) [11], and highlights a need for ongoing rapid insights that can
inform these decisions. These insights are generally provided via data from randomized controlled trials (RCTs)
and/or through the generation of real-world evidence (RWE). RWE is often able to provide information that would
not be readily attainable through RCTs, generating data reflective of routine clinical practice in broader, real-life
treatment populations. Within the lung cancer drug development arena, there are many examples of the usefulness
of RWE in providing complementary data to reinforce and support clinical trial data. For example, recent real-world
studies have evaluated the safety and/or effectiveness of lung cancer treatments, often in patient cohorts ineligible
for clinical trials [12–15]; investigated the real-world burden of lung cancers and related treatment patterns and
survivorship [13,14,16–18]; and assessed treatment-related costs/healthcare resource utilization (HCRU) [13,14,16,19].
As such, data from both observational real-world studies and traditional RCTs are important in informing best
clinical practice, and regulatory bodies are now recognizing that these two methodologies are complementary in
both the pre- and postauthorization stages of drug development [20,21].
Despite providing useful information, many existing RWE initiatives are limited in scope. Although the specific
reasons vary, this may be due to a relatively short length of follow-up, restricted geographical coverage (i.e., only
covering a single region or country), niche study populations with limited generalizability or long lead times
from inception to data generation. Furthermore, many current real-world data sources (RWDS) were designed for
auditing as opposed to research purposes and, therefore, are often unable to address more than a relatively small
set of research objectives. With a rapidly evolving treatment landscape, these limitations may represent barriers to
gathering timely insights on the treatment of lung cancers. One approach to mitigate these limitations, which has
been adopted in other therapy areas [22,23], is to leverage multiple independent data sources (e.g., both electronic
case report forms/electronic medical records [eCRF/EMR] and national registries) from different countries and
regions with ongoing follow-up in order to develop a broader and more robust research platform that can address
a wider array of research objectives and track changes over time.
This approach forms the basis of I-O Optimise, an ongoing collaborative initiative aimed at developing a
multinational research platform that will leverage existing RWDS to provide continuous insights into the evolving
thoracic malignancies landscape. In this article, we provide an overview of the development of a collaborative
real-world research platform by describing the conception and creation of I-O Optimise, with a focus on the
associated methodology and research prospects.
Materials & methods
I-O Optimise organization
Plans for research outputs from I-O Optimise are designed and analyses performed in a collaboration between
the respective RWDS owners, the initiative facilitator (IQVIA), and the initiative sponsor (Bristol-Myers Squibb).
Each RWDS has a specific contractual agreement with the initiative facilitator and sponsor; however, the respective
RWDS retain full ownership of their data, with access permitted to the initiative facilitator and sponsor only in
alignment with I-O Optimise research objectives and the related analyses.
As part of I-O Optimise, an external scientific committee comprised of a multinational, multidisciplinary team of
experts (clinicians/oncologists, epidemiologists, health economists and RWDS owners) was convened. The primary
role of this committee is to provide continuous insights and guidance on the latest medical and epidemiologic
knowledge, to ensure deployment of the most rigorous methodological approaches during data analyses and to
ensure that research outputs are independently verified. In addition, under the auspices of the I-O Optimise
initiative, the external scientific committee meets regularly with other RWDS owners, leading clinicians and patient
advocates to discuss the role of RWE in addressing challenges in lung cancer care, and to gain input on the initiative
research priorities and objectives.
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Table 1. Scope of I-O Optimise.
Topics Research objectives
Epidemiology and clinical outcomes • Understand thoracic malignancy landscape by describing patient demographics and clinical characteristics
• Understand real-world effectiveness of treatments
• Investigate impact of alternative treatment patterns on clinical outcomes
• Explore patient subpopulations and associated outcomes
Treatment patterns • Document current and emerging lung cancer clinical care pathways and treatment patterns
• Explore context for usage and duration of therapy (immunotherapies and other SACT)
• Investigate the biomarker testing flow and role in treatment decisions
Safety • Understand the frequency of AEs for different treatments and for different patient subgroups
• Evaluate the impact of AEs on treatment duration
Healthcare resource utilization • Understand costs of treatment, care and patient management
• Assess economic value of treatments (immunotherapies and other SACT)
Patient-reported outcomes • Explore health-related quality of life of patients with lung cancer
AE: Adverse event; SACT: Systemic anticancer therapy.
Scope of I-O Optimise
The key research objectives of I-O Optimise are shown in Table 1 and were defined, following input from a broad
range of stakeholders, to ensure that I-O Optimise insights are relevant to those involved in patient care.
Data sourcing process
To identify the most suitable data sources to address the defined research objectives, a three-step approach was
followed: data source identification and selection; initial assessment of data sources; and full assessment of data
sources (Figure 1).
Data source identification & selection
Different types of observational data from various countries (with an initial focus on Europe) were evaluated for
inclusion in I-O Optimise. Data sources were identified via desk research (including a targeted literature review
and background research) and interviews with disease area specialists. Data sources were shortlisted based on the
size of the population catchment area, expected disease coverage (NSCLC, small-cell lung cancer [SCLC] and
malignant pleural mesothelioma), number of new patients with lung cancer per year and prior research experience.
Data sources were further prioritized (high, medium, low) in each country to ensure outreach efforts were focused
on the RWDS most likely to have the ability to address the key research objectives.
Initial assessment of data sources
Initial assessment provided a preliminary view on the ability of the data sources to address I-O Optimise research
objectives. Data source owners completed a set of semistructured questionnaires, based on variables needed to
address the research objectives and on the nature of the RWDS. The short questionnaire, completed via email,
was used to obtain a high-level overview of the data source (e.g., population coverage, data availability and
ethics approval requirement). A longer, in-depth questionnaire, completed via telephone, was used to evaluate the
finer details of the database (e.g., patient numbers per malignancy, number of patients added annually, presence
or absence of desired variables, frequency of data collection and recording, restrictions to data access, existing
infrastructure to support research and previous publications). Responses to the questionnaires were assessed against
the five core research areas: clinical outcomes, treatment patterns, frequency of adverse events (AEs), HCRU and
patient-reported outcomes. Data were not analyzed at this stage of the process. The ability of the data source to
address research objectives was based on the self-reported presence/absence of the mandatory variables for each
research area (i.e., the data source owner indicated which variables were covered by their database as part of the
questionnaire responses). The decision on whether a data source should proceed to full assessment was based on
the ability of a data source to address the research questions, the population coverage and representativeness, the
need and possibility of linkage to other data sources, the level of engagement with the data source owners and the
ability to address research questions that other data sources are less able to address (thereby increasing the strength
of the portfolio).
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1. Data source identification and selection
Shortlist criteria:
• Geography
• Population catchment area
• Expected disease coverage (NSCLC, SCLC, mesothelioma)
• Number of new patients with lung cancer per year
• Prior research experience
2. Initial assessment of data sources
3. Full assessment of data sources
Operational assessmentQuantitative assessmentQualitative assessment
Criteria to progress to full assessment:
• Ability to address research objectives
• Population coverage and representativeness
• Need and possibility of linkage to other data sources
• Level of engagement with data source owners
• Ability to address research questions that other data sources 
are less capable of addressing (strength of the portfolio)
Portfolio assessment
• Research logistics
• Extraction costs
• Publication arrangements
• Ethics
• Intellectual property
• Presence of desired variables
• Structural assessment
(i.e., volume of usable records)
• Logical consistency
• Data completeness
• Purpose of the database
• Method for data collection 
• Approptiate continuity of 
data collection
• Population coverage
• Confidence in ability to
capture patient follow-up
• Patient selection criteria
• Quality checks
• Research experience
Figure 1. Data sourcing process.
NSCLC: Non-small-cell lung cancer; SCLC: Small-cell lung cancer.
Full assessment of data sources
The full assessment process involved qualitative, quantitative and operational assessments. Qualitative aspects as-
sessed included the initial purpose of the database, methods for data collection, appropriate continuity of data
collection (i.e., time between data collection and data availability for analysis), population coverage (representative-
ness), confidence in the ability of the database to appropriately capture patient follow-up, patient selection criteria,
quality checks performed on the data source and the research experience of the individuals affiliated with the
data source. The quantitative aspects assessed included: presence of desired variables, structural assessment, logical
consistency and data completeness. It was conducted in four steps: assessment of variable coverage (120 variables
related to the research objectives); preparation of a data set extract by the data source owners, covering all available
variables; completion of the analyses; and review and discussion of analysis results with the data source owners. The
following key analyses were conducted: linkage checks, to verify the total volume of usable records; logic checks,
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594 RWDS identified
173 (29.1%) shortlisted
36 (20.8%) shortlisted
for initial assessment
Six have been 
approached
One undergoing 
initial assessment
29 completed
initial assessment
137 (79.2%) excluded:
• Nonresponders
• Not suitable for participation
• Rejected participation
421 (70.9%) excluded:
• Small population catchment area
• No thoracic malignancy patients
• Data are no longer collected/recorded
• RWDS de-prioritized over data sources
with higher potential in the country
Figure 2. Data source identification and selection flow.
RWDS: Real-world data source.
to identify the number of illogical data entries; counts across years, to verify the number of new patients per year
and the number of patients receiving active treatment per year; distribution checks, to provide insight into the
frequency of distribution of key variables, allowing assessment of whether the content of these variables is logical
and broadly as expected; data completeness checks; and patient follow-up checks, to assess the median length of
follow-up for patients. The operational assessment evaluated various areas including research logistics, extraction
costs, publication arrangements, ethics and intellectual property. The assessment was conducted via regular calls
and face-to-face meetings with data source owners.
Portfolio assessment
Following completion of the full assessment, a group of experts from across the program evaluated (and will
continue to evaluate) the results of the assessments, and decided upon full engagement with the respective data
sources.
Data protection
All data analyzed under the auspices of I-O Optimise are aligned with specified study protocols that are approved
by the relevant authorities in compliance with the country-specific regulatory processes for each RWDS. Data
are analyzed at a population level and are, therefore, anonymized. Publication and presentation of data from I-O
Optimise will adhere to the relevant ethics agreements of the respective RWDS and will be compliant with the
European Union General Data Protection Regulation.
Results
Data source identification & selection
As of the cut-off date for this article (31 October 2018), a total of 594 RWDS had been considered for inclusion
in I-O Optimise, with 173 shortlisted and approached for participation in the initial assessment process (Figure 2).
From these 173 RWDS, 36 were selected to participate. Reasons for excluding RWDS were: nonresponses (n = 60);
data sources not being suitable for the project, for example, no continuous data collection, thoracic malignancies
not covered, overlap with other selected data sources (n = 58); or the data source refusing to participate (n = 19).
In total, 29 RWDS had completed the initial assessment process by 31 October 2018, with 12 selected for full
assessment; five awaiting a decision; and the remaining 12 excluded due to limited sample size (n = 5), unsuitable
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Figure 3. Initial assessment of results.
†View presented is based on enhanced data.
AE: Adverse event; NSCLC: Non-small-cell lung cancer; SCLC: Small-cell lung cancer.
database content/structure (n = 3), insufficient population coverage (n = 2), overlap with another selected data
source (n = 1) or disengagement (n = 1) (Figure 3). In addition to the 12 RWDS selected via the initial assessment
process, three linked data sources from Scandinavia were preidentified through an ongoing epidemiology project in
NSCLC and selected for inclusion without initial assessment, giving a total of 15 data sources for full assessment.
Following evaluation of the full assessment report for each data source on 31 October 2018, seven data sources
were included in the initial build of I-O Optimise. The remaining eight data sources were still undergoing full
assessment at this cut-off date.
Overview of RWDS selected for I-O Optimise
The seven data sources included in the initial build of I-O Optimise have a wide geographic coverage, including
patients from Denmark, Norway, Portugal, Spain, Sweden and the UK (Table 2). The selected RWDS have a broad
mix of data source type (registry data alone, linked EMR and registry data, hospital EMR data alone and data
recorded in a hospital eCRF) and practice coverage (single hospital, all public hospitals in one region, multiple
hospitals across a country and national registries). Thus, some sources will provide data on epidemiology and
patterns of care for patients with lung cancer in the given country population, while others will provide a deep
examination of patient and disease characteristics and treatments within a patient population referred to a cancer
hospital or medical oncology practice. All data sources currently included have no formalized patient selection
criteria, with patients being registered as soon as they have been seen at the sites covered by the data source. Where
data are available, the average number of incident cases captured per year ranged from 435 to 30,900 for NSCLC,
and from 49 to 4262 for SCLC. For mesothelioma, six of the seven data sources are suitable for inclusion in I-O
Optimise based on sample size; the seventh has fewer than ten incident cases registered per year and is, therefore,
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Table 2. I-O Optimise database overview: based on full assessments performed by cut-off date for this article (31 October
2018).
Data sources
1 2 3 4 5 6 7
Type of data source Linked hospital
EMR and
regional cancer
registry
Hospital eCRF Hospital EMR National cancer
registry
National
registries
(including
cancer registry)
Linked hospital
EMR and
national
registries
(including
cancer registry)
National registries
(including cancer
registry)
Practice coverage Single hospital Hospitals from
multiple sites
across the
country
All hospitals in
one region
National
coverage
National
coverage
Hospitals from
multiple sites;
national
coverage
National coverage
Inclusion/exclusion criteria No No No No No No No
Average number
of incident
patients per
year
NSCLC 435 N/A 1119 30,900 1881 2943 (registry)
478 (EMR)
3126
SCLC 49 N/A 159 4262 419† 56† 626†
Mesothelioma 3 N/A 71 355 47† 93† 57†
Data capture Data availability 2012–present 2016–present 2006–present 2012–present 2005–present 2005–present 2005–present
Data lag time 6 months Variable‡ 24 hours 9 months 12 months 7–13 months 7–12 months
†For the registries, these represent indicative numbers per malignancy.
‡Records are updated via eCRF and input frequency will vary by hospital.
eCRF: Electronic case report form; EMR: Electronic medical record; N/A: Not available; NSCLC: Non-small-cell lung cancer; SCLC: Small-cell lung cancer.
deemed unsuitable for mesothelioma. Among these six data sources, the average number of incident mesothelioma
cases per year ranged from 47 to 355. The data sources provide far-reaching data capture with data availability from
2005 up to the present day. Lag times for the data sources vary, and where available range from 24 h to 13 months
(Table 2). All data sources included in the initial build of I-O Optimise have affiliated researchers with a high level
of experience; most (six) have owners who have published an extensive list of relevant peer-reviewed journal articles
in the area of oncology. In addition, a wide variety of researchers are involved in the RWDS, including clinical
researchers, qualified epidemiologists and statisticians with oncology oversight.
Figure 4 shows the key variables covered by the seven RWDS. In terms of clinical characteristics, tumor histology
and staging at diagnosis are captured in all data sources in a structured format (i.e., data were prospectively
collected). The availability of data on other clinical characteristics varies between the RWDS, although the majority
of variables are available in either a structured or unstructured (e.g., in EMR free text) format. In terms of treatment
data, most (four) RWDS capture structured information related to systemic anticancer therapy (SACT), including
drug names and dates of infusion (or prescription for oral treatment). Surgery information is captured through
procedure codes in all except one data source; due to the specificity of the coding system, in most cases this will
allow for the identification of the date, localization and type of surgery. For one data source, surgery information is
captured in a structured format in the eCRF. Like surgery, radiotherapy information is mainly captured (in all but
one data source) through procedure codes. However, unlike surgery codes, radiotherapy codes are less specific and
only very limited information will be available on the localization, type, dose and fractionation of radiotherapy.
Again, in one data source, radiotherapy information will be detailed in the eCRF. In terms of outcomes data, all
seven data sources include information on overall survival. For all the data sources except one, date-of-death data
are cross-checked with the national death registry. Structured data for other efficacy outcomes are currently only
captured in a small number of RWDS. Regarding safety outcomes, data availability will be variable; for example, in
one data source only those AEs leading to treatment change will be captured. However, AE information may not
always be captured in patient records, and there may be a lack of consistency in the reporting terminology. None
of the data sources currently included in I-O Optimise were initially collecting data on health-related quality of
life, but one RWDS started capturing EuroQoL-5D quality of life questionnaire outcomes among all patients from
2018 onward. Data on HCRU are available in five RWDS, being limited to the care delivered in the single hospital
covered for each data source. Actual cost data are likely to be limited, although generalized costs may be calculated
from the available HCRU data.
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Key variables 
Data sources 
1 2 3 4 5 6 7 
Clinical characteriscs 
Age and gender        
Histology        
        
TNM stage at diagnosis        
TNM stage over me        
Metastasis localizaon at diagnosis        
Metastasis localizaon over me        
Biomarker status        
Performance status at diagnosis† (From 2018)       
Smoking status at diagnosis        
Comorbidies        
Comedicaons        
Treatment 
SACT (date, duraon, treatments received)        
Surgery (date, localizaon, type of surgery)        
Radiotherapy (date)        
Radiotherapy (localizaon, type of radiaon, dose)††        
Outcomes 
Death date (OS)        
Tumor progression date (PFS)        
Treatment response (From 2018)       
AEs        
HRQoL (From 2018)       
HCRU§        
Variable captured in a structured format. 
Variable captured in an unstructured format (e.g., EMR free text) or limited informaon available. 
Not available. 
†Based on Eastern Cooperave Oncology Group/World Health Organizaon, and/or Karnofsky criteria. 
††Data availability depends on radiotherapy codes ulized in data capture. 
§Hospital stay, outpaent visits, consultaons with GP or specialists, procedures, tests. 
AE: adverse event; EMR: electronic medical record; GP: general praconer; HCRU: healthcare resource ulizaon; HRQoL: health-related quality of life; OS: overall 
survival; PFS: progression-free survival; SACT: systemic an-cancer therapy; TNM: tumor, nodes, and metastasis. 
Figure 4. I-O Optimise key variables. Based on full assessments performed by cut-off date for this article (31 October 2018).
As shown in Figure 4, in many cases the data variables are captured prospectively in a structured format. However,
when only unstructured data are available, additional efforts have been (and will continue to be) undertaken to
successfully recover the information from EMR free text. Moreover, where other information is missing, relevant
algorithms will be developed, validated and utilized for data capture. For example, treatments in oncology are
generally described by line of therapy, driving treatment recommendations, but this parameter is often not captured
in RWDS. In I-O Optimise, algorithms will be used to appropriately identify the different regimens received, and
the sequencing of those different regimens, to define the line of therapy. A similar approach is being applied to
describe the initial treatment given after diagnosis, taking into account the information on surgery, radiotherapy
and SACT. As the initiative evolves, other algorithms may be developed.
Discussion
I-O Optimise, a novel, multinational research framework based on multiple RWDS, was established in response to
a need for more robust, ongoing and timely RWE on the long-term outcomes with emerging treatments for thoracic
malignancies. To maximize the utility of I-O Optimise, the RWDS selection process was rigorous. From almost
600 RWDS originally identified, only 15 were selected for full assessment. Moreover, the data source selection
process followed for I-O Optimise adhered closely to the ‘database selection’ checklist proposed by Hall et al. [24],
whereby a focus was placed on the population covered (i.e., unbiased patient selection), the capture of key variables
of interest (i.e., good-quality data), the continuous and consistent capture of data (i.e., long-term data availability),
the record duration and data latency (i.e., relatively consistent lag times) and the database expertise (i.e., evidence
of peer-reviewed publication expertise).
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As of the cut-off date for this article (31 October 2018), seven data sources were included in the initial build
of I-O Optimise. The strengths of the current RWDS include a wide geographic reach, large thoracic malignancy
populations, a variety of data source types and far-reaching data capture (from 2005 up to the present day). Among
the seven data sources currently selected, all will provide a variety of data (see Figure 4) on clinical characteristics
(including characteristics at baseline and, for some variables, how these characteristics evolve over time), treatment
patterns and outcomes. Indeed, some of the data sources included in I-O Optimise have already produced interesting
and insightful data [25–28]. An additional feature of I-O Optimise is that, through the additional processes of assessing
eCRF/EMR free text for unstructured data and developing relevant algorithms for missing data, the quality of
the research outputs can be further enhanced. Similar algorithms have been used successfully for the assessment
of treatment patterns/sequences among patients with colon cancer, breast cancer and sarcoma [29–35]. Crucially,
the algorithms developed as part of I-O Optimise will be used consistently across the different RWDS, further
strengthening the generalizability of the data findings.
While the focus of this report is on the characteristics of the currently included RWDS, it is important to
note that, although not all RWDS capture all variables of interest, the selection process was based on including
a collection of different data sources to provide an overall balanced portfolio. The aim of this portfolio of data
sources is to adequately cover the scope of the current research questions, with data from oncology-based referred
populations addressing deep clinical questions and data from broader patient populations addressing questions
related to epidemiology and public health. Furthermore, the I-O Optimise portfolio is also designed to be dynamic
and constantly evolving. As such, the research objectives will be reviewed frequently and revised as needed to adapt
to the changing therapeutic landscape for lung cancers. As a consequence, the RWDS included may change over
time in order to constantly enhance the ability to address those research objectives. In addition, there is also the
possibility of improving already enrolled data sources by working with the data source owners to continuously
enhance and augment how the data are collected. Finally, although a comprehensive merger of data across the I-O
Optimise RWDS will not be possible due to inherent methodological differences between the RWDS, there is the
potential for conducting meta-analyses in specific patient populations across similarly structured data sources.
In establishing I-O Optimise, it was important to understand and consider the potential challenges related to
the approach of bringing together disparate existing RWDS under a single initiative [36]. These challenges include
those addressed by the aforementioned rigorous identification and selection process, such as the need to identify
data sources with a sufficiently established infrastructure to provide data of required quality and completeness
on a continuous basis and with appropriate information and operational governance (i.e., data privacy and site
governance). Moreover, it was, and continues to be, important to acknowledge the challenges that could be faced
when conducting analyses across these RWDS. Indeed, some of the main concerns related to the conduct of
multi–data source initiatives appear to be related to incomplete/missing data and methodological differences [36,37].
For example, in the recently established Real world Outcomes across the Alzheimer’s Disease spectrum for better
care: Multi-modal data Access Platform (ROADMAP) initiative, designed to optimize real-world data generation
in Alzheimer’s disease, a noted challenge is the lack of standardized outcomes across the different data sources [22].
However, these challenges are not insurmountable and will be addressed in I-O Optimise via the development of
appropriate algorithms, as discussed earlier, and through additional efforts to standardize data capture.
Conclusion
As the number of pharmacological treatments for patients with lung cancer increases, there is an increased need for
RWE on long-term outcomes with the various therapeutic options available. Despite this need, many existing lung
cancer RWDS are limited in scope and are unable to focus on more than a small number of research objectives. To
address this challenge, the I-O Optimise initiative was established, enabling the use of multiple RWDS to provide
a broad, robust and dynamic research platform that can continually address numerous research objectives in the
lung cancer arena. Indeed, through ongoing engagement with RWDS owners, along with the ability to capture and
analyze data continuously over a prolonged period, it is hoped that I-O Optimise will allow a thorough assessment
of the evolution of the epidemiology of thoracic malignancies, practice patterns and clinical outcomes over time
with the advance of new therapies, in particular with the increasing use of immunotherapies.
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Summary points
• Although many existing real-world evidence initiatives can provide useful information on the management of
lung cancers, most are limited in their ability to address the dynamic research needs related to a rapidly evolving
treatment landscape.
• Leveraging multiple independent data sources from different countries and regions is one approach to
mitigating these limitations, and can provide a broader and more robust research platform that can address a
wider array of research objectives and track changes over time.
• This approach forms the basis of I-O Optimise, an ongoing collaborative initiative aimed at developing a
multinational research platform that will leverage existing real-world data sources (RWDS) to provide continuous
insights into the evolving thoracic malignancies landscape.
• As of the cut-off date for this article (31 October 2018), 36 data sources had been shortlisted for initial assessment,
with 29 having completed that assessment. Of these 29, 15 were subsequently selected for full assessment.
• At the time of writing, seven RWDS had completed the full assessment and been included in I-O Optimise. These
sources provide data from more than 45,000 patients annually with non-small-cell lung cancer, small-cell lung
cancer and mesothelioma, from sites across Denmark, Norway, Portugal, Spain, Sweden and the UK.
• Additional strengths of the current RWDS include a variety of data source types (registry data alone, linked
electronic medical records and registry data, hospital electronic medical records data alone and data recorded in
an electronic case report form), variable practice coverage (single hospital, all public hospitals in one region,
multiple hospitals across a country and national registries) and far-reaching data capture (from 2005 up to the
present day).
• The I-O Optimise portfolio is designed to be dynamic and constantly evolving, and the research objectives will be
reviewed frequently and revised as needed to adapt to the changing therapeutic landscape for lung cancers. As a
consequence, the RWDS included may change over time in order to constantly enhance the ability to address
those research objectives.
• The ongoing I-O Optimise initiative will provide a broad, robust and dynamic research platform that will
continually address numerous research objectives in the lung cancer arena.
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